Rank Ligand Inhibitor Segment Expected to Realize the Fastest Growth (4.3% CAGR) in the Global Osteoporosis Drugs Market, During 2016 – 2022

The global osteoporosis drugs market was valued at $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various classes of osteoporosis drugs, the rank ligand inhibitor segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period.

The global osteoporosis drugs market is growing at a significant rate due to growing geriatric population, increasing awareness of osteoporosis and increasing healthcare expenditure. The increasing prevalence of osteoporosis in postmenopausal women and the increasing focus on research & development of new drugs for treatment of osteoporosis are also driving the growth of the global osteoporosis drugs market.

Explore Detailed Description of the Report at: https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed by bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. The factors such as strict regulatory requirement for the approval of osteoporosis drugs, patent expiry of blockbuster drugs, and side-effects and complications associated with osteoporosis drugs are inhibiting the growth of the global market. 

Explore More Report at: https://www.psmarketresearch.com/industry-report/healthcare

Geographically, North America dominated the global market of osteoporosis drugs in 2015; whereas the Asia-Pacific market is expected to witness the fastest growth, a CAGR of 4.2% during the forecast period. This is due to the growing geriatric population, increasing awareness of osteoporosis drugs and increasing healthcare expenditure in the region.

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc. and Amgen Inc.


By Drug Class

  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERM’s)
  • Rank Ligand Inhibitor
  • Calcitonin
  • Others

By Geography

  • North America
    • U.S.
    • Rest of North America
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Rest of the World (RoW)


About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Web: https://www.psmarketresearch.com

Media Contact
Company Name: P&S Market Research
Contact Person: Deep, Assistant – Client Partner
Email: enquiry@psmarketresearch.com
Phone: +1-888-778-7886 (USA/Canada Toll-Free)
Address:347, 5th Ave. #1402
City: New York City
State: NY
Country: United States
Website: https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market